Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.

ABSTRACT:

Background

Amid continued uncertainty about the management of cancer patients during the pandemic, this study sought to obtain real-world data on the use of immune checkpoint inhibitors (ICIs) before COVID-19 diagnosis and its association with severity and survival outcomes in cancer patients who contracted COVID-19.

Methods

Cancer patients diagnosed with COVID-19 were identified from a large electronic health record database; those treated with ICIs before COVID-19+ diagnosis were matched in a 1:2 ratio to those not treated with ICIs, using a 2-step matching procedure. A descriptive analysis examined the difference in COVID-19 mortality (30-day and overall) and severity outcomes between the 2 cohorts, and overall survival was compared.

Results

Among 17 545 adults ≥18

SUBMITTER: Tan R 

PROVIDER: S-EPMC8914490 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature